ATX inhibitor 5

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC 50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently In Vitro ATX inhibitor 5 (compound 10g) (IC 50 s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC). ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: CFs and t-HSC/Cl-6 cells Concentration: 0.0001, 0.01, 1, 100, 10000 µM Incubation Time: 48 hours Result: Displayed activities against CFs and t-HSC/Cl-6 cells with IC 50 s of 1.21 and 0.78 µM, respectively. In Vivo ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Konmin mice (8-week old, 22-25 g) Dosage: 20, 40 mg/kg Administration: Orally; once daily for two weeks Result: Prominently reduced CCl4-induced hepatic fibrosis level. Form:Solid IC50& Target:Autotaxin

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet